Document is current
Any future updates will be listed below
-
Authors
D’Antongiovanni, Vanessa
Pellegrini, Carolina
Benvenuti, Laura
Fornai, Matteo
Di Salvo, Clelia
Natale, Gianfranco
Ryskalin, Larisa
Bertani, Lorenzo
Lucarini, Elena
Di Cesare Mannelli, Lorenzo
Ghelardini, Carla
Nemeth, Zoltan H.
Haskó, György
Antonioli, Luca https://orcid.org/0000-0003-1241-617X
-
Funding
Funding for this research was provided by:
Nippon Chemiphar Ltd
- License Information
-
More Information
Article History
Received: 23 December 2021
Revised: 14 February 2022
Accepted: 14 March 2022
First Online: 26 March 2022
Change Date: 24 July 2022
Change Type: Update
Change Details: Missing Open Access funding information has been added in the Funding Note
Change Date: 14 September 2024
Change Type: Correction
Change Details: This article has been retracted. Please see the Retraction Notice for more detail:
Change Details: https://doi.org/10.1007/s10753-024-02143-x
Declarations
:
: The experiments have been approved by the Ethical Committee for Animal Experimentation of the University of Pisa and by the Italian Ministry of Health (authorization n 674/2016-PR).
: All the authors have read the manuscript and agreed to submit the paper to the journal.
: The authors declare no competing interests.
: The use of P2X4 antagonists as medicament for preventing or treating irritable bowel syndrome or inflammatory bowel diseases has been patented (PCT/IB2020/053313).
